DelveInsight launched a new report on Metastatic Colorectal Cancer Market Insights, Epidemiology and Market Forecast 2030.
DelveInsight’s ‘Metastatic Colorectal Cancer (mCRC) Market Report 2030’ report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
About the Disease:
Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped together because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.
Metastatic Colorectal Cancer Treatment Therapies:
1. Radiation therapy
2. Immunotherapy
3. Chemotherapy
Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market
Metastatic Colorectal Cancer Epidemiology insights:
- The incident population of CRC in the seven major markets was 518,742 in 2017.
- The incident population of mCRC in the seven major markets is estimated to be 213,181 in 2020.
- In the United States, the number of males and females with CRC is estimated to be 89,527 and 63,773, respectively, in 2020.
Metastatic Colorectal Cancer Therapy Assessment:
1. Braftovi (encorafenib) + Erbitux (cetuximab)/ Braftovi + Mektovi: Array BioPharma/ Pfizer
2. Keytruda (pembrolizumab) injection: Merck
3. Nivolumab (Opdivo) + Ipilimumab (Yervoy): Bristol-Myers Squibb
4. Lonsurf: Taiho Oncology
Metastatic Colorectal Cancer Market Outlook
Colorectal cancer (CRC) is the second most frequent type of cancer that represents approximately 12–14% of all cancer cases in men and women. Out of these, approximately 25% of patients present with metastases at initial diagnosis and almost 50% may eventually develop metastases, contributing to the high mortality rates reported for CRC. In order to identify the optimal treatment strategy for patients with mCRC, tumor staging is essential and should include at least clinical examination, blood counts, liver and renal function tests, CEA, and CT scan of the abdomen and chest (or alternatively MRI).
The treatment plan may include a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, which can be used to slow the spread of the disease and often temporarily shrink a cancerous tumor. Palliative care is also important to help relieve symptoms and side effects.
Click here and get more useful insights from our report.
Key facts from our report:
- The market size of mCRC in the seven major markets is estimated to be USD 12,682 Million in 2020.
Table of contents:
1 Key Insight
2 Executive Summary of Metastatic Colorectal Cancer
3 Metastatic Colorectal Cancer Market Overview at a Glance
4 Disease Background and Overview: Metastatic Colorectal Cancer
5 Case Reports
6 Metastatic Colorectal Cancer Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Metastatic Colorectal Cancer Treatment and Medical Practices
11 Unmet needs
12 Metastatic Colorectal Cancer Marketed Drugs
13 Metastatic Colorectal Cancer Emerging Drugs
14 Metastatic Colorectal Cancer 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Metastatic Colorectal Cancer Market Drivers
19 Metastatic Colorectal Cancer Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight
Download full report @https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/